A Single-Arm, Open-Label Pharmacokinetic, Safety, and Efficacy Study of ASTX727 in Combination with Venetoclax in Adult Patients with Acute Myeloid Leukemia - ASTX727-07

Taiho Oncology Inc.0 个研究点目标入组 160 人开始时间: 2024年8月5日最近更新: 2024年8月21日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: Taiho Oncology Inc.
入组人数: 160

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 至 65+（—）
性别: All

入选标准

•Participant must be 18 years of age or older, Histological confirmation of newly diagnosed AML by World Health Organization (WHO) 2016 criteria (Swerdlow et al 2017)., Projected life expectancy of at least 3 months., Participants must be considered ineligible for intensive induction chemotherapy defined by the following: a) Age 75 years or older, or b) Age 18 to 74 years with at least one of the following comorbidities: i) Severe cardiac disorder (eg, congestive heart failure requiring treatment, ejection fraction =50%, or chronic stable angina). ii) Severe pulmonary disorder (eg, diffusing capacity of the lung for carbon monoxide (DLCO) =65% or forced expiratory volume in 1 second [FEV1] =65%). iii) Creatinine clearance =30 mL/min to <45 mL/min. iv) Moderate hepatic impairment with total bilirubin >1.5 to =3.0 ×upper limit of normal (ULN). v) Phase 1: Eastern Cooperative Oncology Group (ECOG) Performance Status of 2 (subjects with ECOG =3 are not eligible); Phase 2: ECOG Performance Status of 2 or 3 (subjects with ECOG 4 are not eligible)., For Phase 1, ECOG 0-2. For Phase 2, ECOG 0-3. Sex and Contraceptive Barrier Requirements, Participant can be male or female. Due to section size limitations, please refer to Protocol Section 10.2 for contraception requirements., Capable of giving legally effective informed consent (as described in Appendix 1 [Section 10.1.3]), which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol, and willing to participate in the study.

排除标准

•History of myeloproliferative neoplasm including myelofibrosis, essential thrombocythemia, polycythemia vera, chronic myeloid leukemia with or without BCR-ABL1 translocation and AML with BCR-ABL1 translocation., Significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, hepatic, cardiovascular or pulmonary disease, any other medical condition or known hypersensitivity to any of the study medications that in the opinion of the investigator would adversely affect his/her participating in this study., Clinically significant uncontrolled systemic infection requiring therapy (viral, bacterial, or fungal)., History of other malignancies prior to study entry, with the exception of adequately treated in situ carcinoma of the breast or cervix uteri; localized basal cell carcinoma or squamous cell carcinoma of the skin; previous malignancy confined and surgically resected (or adequately treated and controlled with other modalities); and any early stage malignancy for which no definitive therapy is required., WBC count >25,000/µL. (Hydroxyurea treatment is permitted to meet this criterion.), Treatment with the following: a) A hypomethylating agent (azacitidine or decitabine), or venetoclax including prior treatment for MDS. b) Chimeric Antigen Receptor (CAR)-T cell therapy. c) Investigational therapies for MDS or AML., Participants who cannot discontinue concomitant prophylactic antifungal therapy with CYP3A inhibitor activity or other concomitant medications with moderate or strong CYP3A inhibitor activity =7 days or 5 half-lives, whichever is greater, prior to C1D1., Participants who cannot discontinue concomitant drugs that are strong CYP3A or P-gp inhibitors =7 days or 5 half-lives, whichever is greater, prior to C1D1., Participants who cannot avoid concomitant drugs known as moderate or strong CYP3A inducers, Current participation in another research requiring interventions such as drug therapy or study procedures, Known or suspected hypersensitivity to decitabine, cedazuridine, venetoclax, or any of their excipients, The following karyotype abnormalities: t(8;21), inv(16) or t(15;17), or other acute promyelocytic leukemia variants that remain sensitive to all-trans retinoic acid (ATRA) therapy, Known significant mental illness or other condition such as active alcohol or other substance abuse or addiction that, in the opinion of the investigator, predisposes the subject to high risk of noncompliance with the protocol., Patients who consume grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or starfruit =7 days prior to C1D1, Known active central nervous system involvement from AML., Known human immunodeficiency virus (HIV) infection (due to potential drug-drug interactions between antiretroviral medications and venetoclax). Human immunodeficiency virus testing will be performed at Screening, only if indicated per local guidelines or institutional standards., Known active hepatitis B or C infection (detectable viral load). Hepatitis B or C testing will be performed at Screening, only if indicated per local guidelines or institutional standards., Severe hepatic impairment defined as: bilirubin >1.5×upper limit of normal (ULN) for subjects =75 years or >3×ULN for subjects <75 years; or aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) or alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT) >3×ULN (unless abnormal

研究者

发起方

Taiho Oncology Inc.

相似试验

进行中（未招募）

1 期

A clinical trial to be conducted in many hospitals and in different countrieswith the medicinal substance Regadenoson to be used in a type of heart scan called ‘radionuclide myocardial perfusion imaging’ to see the blood flow in the heart muscle in patients aged between 1 month - 18 years.Patients who need to undergo a clinically indicated pharmacologic stress perfusion CMR test and who are considered fit for a pharmacological stress perfusion CMR by the investigator. The pharmacologic stress perfusion CMR may be performed in patients for further evaluation of cardiovascular conditions or diseases, such as, but not limited to, Kawasaki disease, congenital heart diseases, congenital coronary abnormalities, and post-cardiac surgery / transplantation, etc.MedDRA version: 20.1Level: LLTClassification code 10028603Term: Myocardial perfusion scanSystem Organ Class: 100000004848MedDRA version: 20.0Level: LLTClassification code 10065141Term: Vascular diagnostic procedureSystem Organ Class: 100000004848

EUCTR2019-002615-25-GBGE Healthcare Ltd.54

进行中（未招募）

1 期

EUCTR2019-002615-25-GRGE Healthcare Ltd.54

进行中（未招募）

1 期

A clinical trial to be conducted in many hospitals and in different countries with the medicinal substance Regadenoson to be used in a type of heart scan called 'radionuclide myocardial perfusion imaging' to see the blood flow in the heart muscle in patients aged between 1 month - 18 year.

EUCTR2019-002615-25-ITGE HEALTHCARE54

进行中（未招募）

1 期

EUCTR2019-002615-25-FRGE Healthcare Ltd.54

已完成

1 期

A clinical trial to check activity of certain enzymes in the body after taking a drug called AEB071

CTRI/2009/091/000582ovartis Healthcare Pvt. Ltd.18